FDA Allows Broader Indications For Oncology Companion Dx’s

New guidance from the US agency discusses how manufacturers can pursue broader indications for oncology companion diagnostics. The move could make it easier for clinicians to find the best treatment for each patient.

FDA entrance sign 2016

A new companion diagnostic guidance document from the US Food and Drug Administration could make it easier for clinicians to determine the best treatment for oncology patients, the agency says.

The document, issued on 14 April, gives developers of companion diagnostics for use in oncology treatment additional advice on how to design and test their products to support broader indications...

More from Regulation

More from Policy & Regulation